Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $2.36, $0.19 better than the analyst estimate of $2.17. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.33 billion.

GUIDANCE:

Quest Diagnostics sees FY2022 EPS of $9.75-$9.95, versus the consensus of $9.68.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.